(Q33393031)

English

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th

scientific article

Statements

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th (English)
0 references
0 references
0 references
0 references
0 references
Pierre Fumoleau
Zrinka Mrsic-Krmpotic
Alessandro Riva
29 November 2010

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit